A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both
 ocular and nasal symptoms have a greater burden of illness and lower quality of life than
 patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both
 nasal and ocular symptoms. The purpose of this study was to evaluate the differences in
 symptom control (both perceptually and objectively) and resource use for patients with
 current seasonal AR.
-  Allergic rhinitis (AR) is a common inflammatory condition of the upper respiratory
 tract, nasal cavity and eyes affecting up to 20% of the population in the United States
 and Europe. The bothersome nature of AR symptoms can severely affect daily activities
 including ability to work and examination performance and impact on quality of life
 (QoL) and psychosocial well being.

 -  This study assesses the impact of Fluticasone furoate (FF) on the QoL of seasonal
 allergic rhinitis (SAR) patients, including the number of symptom-free days (SFD) and
 quality of life over the last 4 weeks, and compares this with other inhaled nasal
 steroids (INS): mometasone furate (MF) and fluticasone proprionate (FP).

 -  Selected physicians provide information including a range of demographic, symptom and
 treatment details for a number of their SAR patients. The patient themselves are then
 invited to provide details about their SAR including symptoms, the impact of AR upon
 their lifestyles, attitudes to treatment and completion of Health Related Quality of
 Life (HRQoL) instruments.
Patient Inclusion Criteria:

 -  Current Seasonal Allergic Rhinitis sufferer (based on physician judgement)

 -  Currently receiving prescribed INS treatment (no other treatment restrictions apply)

 -  Have consumed at least one full prescription on the specified INS treatment

 -  No comorbid Asthma or COPD diagnosis

 -  Informed Consent

 Exclusion Criteria:

 -  None specified